National Products Association To Supreme Court: Risk-Benefit Standard Would “Unravel” Dietary Supplement Act
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's risk-benefit standard to determine product adulteration violates Dietary Supplement Health and Education Act "and poses a significant threat" to dietary supplement firms, trade group says in amicus curiae brief.
You may also be interested in...
It's Complicated: FDA Prohibits CBD In Supplements, Enforcement Priority On Disease Claims
As FDA announces its first-ever approval of a drug that contains a substance derived from marijuana, officials say the agency's policy that prohibits CBD's use in dietary supplements or food will not change. They also say, however, that FDA's priority for enforcement actions against dietary supplements containing CBD, an extract from cannabis and hemp plants, will remain on products marketed with drug or disease claims.
Blame China? Experts Advise Congress, Industry Take A Wider View
The global scope of food safety is becoming apparent, and recent problems with products imported from China are but a part of U.S. food safety concerns, industry experts say
Blame China? Experts Advise Congress, Industry Take A Wider View
The global scope of food safety is becoming apparent, and recent problems with products imported from China are but a part of U.S. food safety concerns, industry experts say